The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance

Aidan Toner(Ollscoil na Gaillimhe – University of Galway), Sharon A. Glynn(Dublin City University)
British Journal of Cancer
September 19, 2013
Cited by 12


Related Papers